XMAG - ETF AI Analysis
Top Page
Defiance Large Cap ex-Mag 7 ETF (XMAG)
XMAG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 207.96M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.84
- Issuer
- Defiance
- Inception Date
- Oct 21, 2024
- Dividend Yield
- 0.45%
- Asset Class
- Equity
- Index Tracked
- BITA US 500 ex-Magnificent 7 Index - Benchmark TR Gross
XMAG Summary
XMAG is an ETF that follows the BITA US 500 ex-Magnificent 7 Index, giving you exposure to large U.S. companies while intentionally leaving out the seven biggest tech giants. It spreads your money across many sectors, including technology, finance, health care, and consumer companies. Well-known holdings include Eli Lilly, JPMorgan Chase, Berkshire Hathaway, Exxon Mobil, Visa, Johnson & Johnson, and Walmart. Someone might invest in XMAG for broad diversification in large, established companies without relying too heavily on mega-cap tech stocks. A key risk is that the ETF can still go up and down with the overall stock market.
How much will it cost me?
XMAG has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 invested. That’s a bit higher than the cheapest index ETFs because this fund tracks a more specialized index that excludes the “Mag 7,” which typically costs a little more to run than a plain-vanilla broad market index fund.
What would affect this ETF?
XMAG’s focus on large U.S. companies across technology, financials, health care, and industrials means it could benefit from a strong U.S. economy, rising corporate profits, and continued innovation at top holdings like Eli Lilly, Broadcom, and JPMorgan. However, higher interest rates, economic slowdowns, or sector-specific challenges in tech, banks, or energy, along with the ETF’s exclusion of the “Mag 7” mega-cap tech stocks, could cause it to lag broader market indexes during periods when those giants outperform.
XMAG Top 10 Holdings
XMAG leans heavily into U.S. large caps outside the usual Big Tech crowd, but it still has a strong tech flavor. Micron and AMD are key drivers, with Micron’s powerful year-to-date run and AMD’s rising momentum in data centers helping to pull the fund higher, even after some recent choppiness. Eli Lilly and Johnson & Johnson add steady, rising strength from healthcare, while Exxon Mobil brings energy tailwinds. On the financial side, JPMorgan and Berkshire Hathaway are more mixed, occasionally losing steam and modestly tempering overall performance.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AVGO | Broadcom | 2.52% | $5.19M | $1.56T | -13.38% | 76Outperform |
 MU | Micron | 2.41% | $4.96M | $1.00T | 294.96% | 79Outperform |
 LLY | Eli Lilly & Co | 2.67% | $5.50M | $1.33T | 67.86% | 72Outperform |
 AMD | Advanced Micro Devices | 2.11% | $4.34M | $824.07B | 98.09% | 73Outperform |
 JPM | JPMorgan Chase | 2.08% | $4.29M | $895.92B | 8.92% | 72Outperform |
 BRK.B | Berkshire Hathaway B | 1.74% | $3.59M | $1.16T | 13.37% | 66Neutral |
 XOM | Exxon Mobil | 1.72% | $3.55M | $769.96B | 63.27% | 74Outperform |
 V | Visa | 1.60% | $3.30M | $782.42B | 19.87% | 70Outperform |
 JNJ | Johnson & Johnson | 1.53% | $3.15M | $657.68B | 44.51% | 78Outperform |
 WMT | Walmart | 1.23% | $2.53M | $979.90B | 20.82% | 78Outperform |
XMAG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMAG, the sentiment is Negative. The current price of 25.72 is below the 20-day moving average (MA) of 25.76, below the 50-day MA of 25.78, and above the 200-day MA of 24.58, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 49.01 is Neutral, neither overbought nor oversold. The STOCH value of 76.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XMAG.
XMAG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| XMAG | $25.72 | $29.00(12.75% Upside) | $207.96M | 0.35% | 72Outperform |
 INFO | $27.73 | $34.10(22.96% Upside) | $961.91M | 0.35% | 74Outperform |
 AFLG | $44.27 | $53.19(20.15% Upside) | $933.48M | 0.55% | 74Outperform |
 XVV | $57.72 | $71.35(23.61% Upside) | $902.08M | 0.08% | 74Outperform |
 PTL | $269.36 | $343.57(27.55% Upside) | $888.20M | 0.09% | 70Neutral |
 ROCY | $54.69 | $67.21(22.89% Upside) | $890.97M | 0.35% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XMAG | Defiance Large Cap ex-Mag 7 ETF | 25.72 | 3.58 | 16.19% | |
| INFO | Harbor PanAgora Dynamic Large Cap Core ETF | 27.73 | 3.30 | 13.53% | |
| AFLG | First Trust Active Factor Large Cap ETF | 44.27 | 5.48 | 14.14% | |
| XVV | iShares ESG Screened S&P 500 ETF | 57.72 | 5.42 | 10.37% | |
| PTL | Inspire 500 ETF | 269.36 | 20.84 | 8.38% | |
| ROCY | JPMorgan Equity Premium Yield ETF | 54.69 | 6.65 | 13.83% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.